Patents Assigned to OyaGen Inc.
  • Method for treating coronavirus infections
    Patent number: 11779585
    Abstract: Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections and SARS-CoV-2 infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.
    Type: Grant
    Filed: August 3, 2022
    Date of Patent: October 10, 2023
    Assignee: OYAGEN, INC.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • Method for treating coronavirus infections
    Patent number: 11738025
    Abstract: Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: August 29, 2023
    Assignee: OYAGEN, INC.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • Methods of treating and inhibiting Ebola virus infection
    Patent number: 11617753
    Abstract: Disclosed herein are methods for treating an Ebola virus and inhibiting the transmission and propagation thereof.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: April 4, 2023
    Assignees: OYAGEN, INC., The United States of America, as represented by the Secretary of Health and Human Services
    Inventors: Harold C. Smith, Ryan P. Bennett, Peter Jahrling
  • METHOD FOR TREATING CORONAVIRUS INFECTIONS
    Publication number: 20220378815
    Abstract: Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections and SARS-CoV-2 infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.
    Type: Application
    Filed: August 3, 2022
    Publication date: December 1, 2022
    Applicant: OYAGEN, INC.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS
    Publication number: 20220000860
    Abstract: Disclosed herein are compounds useful for treating and/or preventing HIV infections and the transmission of HIV from an infected subject.
    Type: Application
    Filed: September 14, 2021
    Publication date: January 6, 2022
    Applicant: OYAGEN, INC.
    Inventors: Harold C. SMITH, Ryan P. BENNETT
  • Compounds, compositions, and methods for treating human immunodeficiency virus
    Patent number: 11116762
    Abstract: Disclosed herein are compounds useful for treating and/or preventing HIV infections and the transmission of HIV from an infected subject.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: September 14, 2021
    Assignee: OyaGen, Inc.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • METHOD FOR TREATING CORONAVIRUS INFECTIONS
    Publication number: 20210236497
    Abstract: Disclosed herein are methods, formulations, and kits for treating coronavirus infections, including Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infections. Further disclosed are stop-gap methods for controlling the spread of coronavirus infections and the emergence of drug resistant strains of coronavirus.
    Type: Application
    Filed: April 16, 2020
    Publication date: August 5, 2021
    Applicant: OYAGEN, INC.
    Inventors: Harold C. SMITH, Ryan P. BENNETT
  • CAMPTOTHECIN DERIVATIVES AS ANTI-HIV AGENTS AND METHODS OF IDENTIFYING AGENTS THAT DISRUPT VIF SELF-ASSOCIATION
    Publication number: 20200338067
    Abstract: The present invention relates to the use of camptothecin derivatives as anti-HIV agents that disrupt self-association of the viral infectivity factor (Vif) found in HIV and other retroviruses. The present invention also relates to methods of identifying agents that disrupt VIf self-association and methods of using these agents, including methods of treating or preventing HIV infection.
    Type: Application
    Filed: March 15, 2020
    Publication date: October 29, 2020
    Applicant: OYAGEN, INC.
    Inventors: Harold C. SMITH, Ryan P. BENNETT
  • Camptothecin derivatives as anti-HIV agents and methods of identifying agents that disrupt Vif self-association
    Patent number: 10588902
    Abstract: The present invention relates to the use of camptothecin derivatives as anti-HIV agents that disrupt self-association of the viral infectivity factor (Vif) found in HIV and other retroviruses. The present invention also relates to methods of identifying agents that disrupt VIf self-association and methods of using these agents, including methods of treating or preventing HIV infection.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: March 17, 2020
    Assignee: OyaGen, Inc.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING HUMAN IMMUNODEFICIENCY VIRUS
    Publication number: 20190350925
    Abstract: Disclosed herein are compounds useful for treating and/or preventing HIV infections and the transmission of HIV from an infected subject.
    Type: Application
    Filed: January 2, 2018
    Publication date: November 21, 2019
    Applicant: OYAGEN, INC.
    Inventors: Harold C. SMITH, Ryan P. BENNETT
  • CAMPTOTHECIN DERIVATIVES AS ANTI-HIV AGENTS AND METHODS OF IDENTIFYING AGENTS THAT DISRUPT VIF SELF-ASSOCIATION
    Publication number: 20160143900
    Abstract: The present invention relates to the use of camptothecin derivatives as anti-HIV agents that disrupt self-association of the viral infectivity factor (Vif) found in HIV and other retroviruses. The present invention also relates to methods of identifying agents that disrupt VIf self-association and methods of using these agents, including methods of treating or preventing HIV infection.
    Type: Application
    Filed: June 24, 2014
    Publication date: May 26, 2016
    Applicant: OyaGen, Inc.
    Inventors: Harold C. SMITH, Ryan P. BENNETT
  • SMALL MOLECULES AS ANTI-HIV AGENTS THAT DISRUPT VIF SELF-ASSOCIATION AND METHODS OF USE THEREOF
    Publication number: 20150272959
    Abstract: The present invention relates to the use of small molecules as anti-HIV agents that disrupt self-association of the viral infectivity factor (Vif) found in HIV and other retroviruses. The present invention also relates to methods of identifying agents that disrupt VIf self-association and methods of using these agents, including methods of treating or preventing HIV infection.
    Type: Application
    Filed: October 4, 2013
    Publication date: October 1, 2015
    Applicant: OYAGEN, INC.
    Inventors: Harold C. Smith, Ryan P. Bennett
  • Peptide and treatment for HIV-1 infection
    Patent number: 8334255
    Abstract: A compound of the formula X1-M-SEQ ID NO:1, or a derivative thereof, is provided, wherein X1-M- represents an optional group comprising a protein transduction domain conjugated to the N-terminus of the amino acid sequence SEQ ID NO:1. Pharmaceutical compositions comprising and therapeutic methods using the compound are also provided.
    Type: Grant
    Filed: December 4, 2007
    Date of Patent: December 18, 2012
    Assignees: Thomas Jefferson University, OyaGen Inc.
    Inventors: Hui Zhang, Harold C. Smith
  • PEPTIDE AND TREATMENT FOR HIV-1 INFECTION
    Publication number: 20100029570
    Abstract: A compound of the formula X1-M-SEQ ID NO:1, or a derivative thereof, is provided, wherein X1-M- represents an optional group comprising a protein transduction domain conjugated to the N-terminus of the amino acid sequence SEQ ID NO:1. Pharmaceutical compositions comprising and therapeutic methods using the compound are also provided.
    Type: Application
    Filed: December 4, 2007
    Publication date: February 4, 2010
    Applicants: THOMAS JEFFERSON UNIVERSITY, OYAGEN INC.
    Inventors: Hui Zhang, Harold C. Smith